MedTrace Logo

Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes

NCT00735501 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 314

Last updated 2014-10-29

No results posted yet for this study

Summary

This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.

Conditions

Interventions

DRUG

insulin detemir

Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00735501 on ClinicalTrials.gov